盐酸莫昔普利(Moexipril Hydrochloride) - 药物靶点：ACE_在研适应症：高血压_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Cardiotensin、Femipres、Fempress

+ [13]

靶点

ACE

作用机制

ACE抑制剂(血管紧张素转化酶抑制剂)

治疗领域

心血管疾病

在研适应症

高血压

非在研适应症-

原研机构

Schwarz Profilbeschichtungs GmbH + Co. KG

在研机构-

非在研机构

UCB, Inc.

最高研发阶段批准上市

首次获批日期

美国 (1995-04-19),

高血压

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

结构

分子式C27H34N2O7

InChIKeyUWWDHYUMIORJTA-HSQYWUDLSA-N

CAS号103775-10-6

查看全部结构式(2)

关联

3

项与盐酸莫昔普利相关的临床试验

NCT00992862 / Completed临床1期

A Relative Bioavailability Study of Moexipril HCl 15mg Tablets Under Fasting Conditions

The purpose of this study is to compare the relative bioavailability of Moexipril HCl 15mg tablets (by Paddock Laboratories, Inc.) with that of Univasc® 15mg tablets (by Schwarz Pharma) following a single oral dose (1 x 15mg tablet) in healthy, adult subjects under fasting conditions.

开始日期-

申办/合作机构

Paddock Laboratories, Inc.

NCT01669434 / Completed临床4期IIT

Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery: A Randomized, Single-Blinded Study

Primary research hypothesis: Patients who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively.
Secondary research hypothesis #1: Patients who continue their chronic ACEI up to and including the morning of a non-cardiac, non-vascular surgery will experience better postoperative control of hypertension than those who transiently hold their chronic ACEI preoperatively.
Secondary research hypothesis #2: Patients who continue their chronic ACEI up to and including the morning of a non-cardiac, non-vascular surgery will experience less acute renal failure than those who transiently hold their chronic ACEI preoperatively.
Secondary research hypothesis #3: In the subgroup of patients with a preoperative systolic blood pressure less than 110 mmHg, those who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively.
Secondary research hypothesis #4: In the subgroup of patients above the age of 64, those who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively.

开始日期2015-06-01

申办/合作机构

University of Nebraska

NCT00588302 / Completed临床2期

Open-Label Pilot Investigation of Moexipril for the Treatment of Primary Biliary Cirrhosis (PBC)

The blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We aimed to determine the safety and efficacy of moexipril, an angiotensin-converting enzyme (ACE) inhibitor, on liver biochemistries, Mayo risk score, and health-related quality of life in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA).

开始日期2003-06-01

申办/合作机构

Mayo Clinic

[+1]

100 项与盐酸莫昔普利相关的临床结果

登录后查看更多信息

100 项与盐酸莫昔普利相关的转化医学

登录后查看更多信息

100 项与盐酸莫昔普利相关的专利（医药）

登录后查看更多信息

117

项与盐酸莫昔普利相关的文献（医药）

2024-08-01·Journal of Ethnopharmacology

Synergistic effects of medicinal plants in combination with spices from algeria: Anticancer, antiangiogenic activities, and embrytoxicity studies

Article

作者: Belhouala, Khadidja ; Pandiella, Atanasio ; Benarba, Bachir

ETHNOPHARMACOLOGICAL RELEVANCEBryonia dioica Jacq., Evernia prunastri (L.) Ach., Telephium imperati L., and Aristolochia longa L. are species widely used in traditional medicine to treat several diseases including cancer. Conjugation of two or more extracts is an approach to improve the effectiveness of their pharmacological activities.AIM OF THE STUDYTo evaluate the synergistic anticancer and anti-angiogenic effects of medicinal plants and edible species combinations.MATERIALS AND METHODSIn this work, B. dioica, E. prunastri, Telephium imperati, and Aristolochia longa extracts were conjugated to form four mixtures. The antiproliferative effect of mixtures on several carcinoma cells was examined by MTT assay, and the antiangiogenic activity was estimated through Hen's egg test in vivo. Moreover, in an Ovo model, 35 fertilized Ross eggs were used to test the embryotoxicity of mixtures.RESULTSAt the highest concentration of 200 μg/mL, both mixtures exerted an important cytotoxic effect against human carcinoma cells. The mixture BETE (Bryonia Evernia Telephium Extract) significantly reduced HT-29, PC-3, and A-549 cell viability. Likewise, this mixture strongly suppressed vascularization in vivo at 200 μg/mL. Interestingly, no signs of toxicity on Perdix embryos were recorded within 21 days of treatment. More importantly, the mixture did not have any cytotoxic effect on non cancerous cells.CONCLUSIONTaken together, our results suggest that the synergy between B. dioica, E. prunastri and T. imperati may be promising for developing new anti-cancer treatments.

2023-08-01·Journal of clinical hypertension (Greenwich, Conn.)

Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis.

Review

作者: Kung, Janice Y ; Banh, Hoan Linh ; Liu, Shuang ; Liang, Ling ; Hu, Yiyun

Studies have shown that angiotensin converting enzyme inhibitors (ACEIs) are superior in primary and secondary prevention for cardiac mortality and morbidity to angiotensin receptor blocker (ARBs). One of the common side effects from ACEI is dry cough. The aims of this systematic review, and network meta-analysis are to rank the risk of cough induced by different ACEIs and between ACEI and placebo, ARB or calcium channel blockers (CCB). We performed a systematic review, and network meta-analysis of randomized controlled trials to rank the risk of cough induced by each ACEI and between ACEI and placebo, ARB or CCB. A total of 135 RCTs with 45,420 patients treated with eleven ACEIs were included in the analyses. The pooled estimated relative risk (RR) between ACEI and placebo was 2.21 (95% CI: 2.05-2.39). ACEI had more incidences of cough than ARB (RR 3.2; 95% CI: 2.91, 3.51), and pooled estimated of RR between ACEI and CCB was 5.30 (95% CI: 4.32-6.50) Moexipril ranked as number one for inducing cough (SUCRA 80.4%) and spirapril ranked the least (SUCRA 12.3%). The order for the rest of the ACEIs are as follows: ramipril (SUCRA 76.4%), fosinopril (SUCRA 72.5%), lisinopril (SUCRA 64.7%), benazepril (SUCRA 58.6%), quinapril (SUCRA 56.5%), perindopril (SUCRA 54.1%), enalapril (SUCRA 49.7%), trandolapril (SUCRA 44.6%) and, captopril (SUCRA 13.7%). All ACEI has the similar risk of developing a cough. ACEI should be avoided in patients who have risk of developing cough, and an ARB or CCB is an alternative based on the patient's comorbidity.

2023-06-15·Toxicology and applied pharmacology

In silico and in vitro screening for carcinogenic potential of angiotensin-converting enzyme inhibitors and their degradation impurities.

Article

作者: Regulska, Katarzyna ; Mikolajczyk, Aleksandra ; Matera-Witkiewicz, Agnieszka ; Stanisz, Beata J.

According to some clinical observations, the use of angiotensin-converting enzyme inhibitors (ACEI) may be associated with an increased risk of cancer. The aim of the present study was to screen for the potential carcinogenicity, mutagenicity and genotoxicity of these drugs using in silico methodology. Delapril, enalapril, imidapril, lisinopril, moexipril, perindopril, ramipril, trandolapril, spirapril were thereby analyzed. In parallel, the corresponding degradation impurities, the diketopiperazine (DKP) derivatives, were also investigated. (Q)SAR computer software (VEGA-GUI and Lazar), available in the public domain, was employed. The obtained predictions suggested that none of the compounds tested (from the group of ACE-Is and DKPs) was mutagenic. Moreover, none of the ACE-Is was carcinogenic. The reliability of these predictions was high to moderate. In contrast, in the DKP group, ramipril-DKP and trandolapril-DKP were found to be potentially carcinogenic, but the reliability of this prediction was low. As for the genotoxicity screening, all compounds tested (ACE-I and DKP) were predicted to be active and genotoxic, with moexipril, ramipril, spirapril, and all DKP derivatives within the highest risk group. They were prioritized for experimental verification studies to confirm or exclude their toxic activity. On the other hand, the lowest risk of carcinogenicity was assigned to imidapril and its DKP. Then, a follow-up in vitro micronucleus assay for ramipril was performed. It showed that this drug was genotoxic via aneugenic activity, but only at concentrations exceeding real-life levels. At concentrations found in human blood after standard dose, ramipril was not genotoxic in vitro. Therefore, ramipril was considered safe for human use with a standard dosing regimen. The other compounds of concern (spirapril, moexipril and all DKP derivatives) should be subjected to analogous in vitro studies. We also concluded that the adopted in silico software was applicable for ACE-I toxicity prediction.

100 项与盐酸莫昔普利相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00623	盐酸莫昔普利	C09AA13	DB00691

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
高血压	黎巴嫩	-	1997-07-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01669434 (CTgov)	临床4期	低血压	291	LISINOPRIL+Captopril+ENALAPRILAT+BENAZEPRIL HYDROCHLORIDE+PERINDOPRIL ERBUMINE+RAMIPRIL+QUINAPRIL HYDROCHLORIDE+Enalapril Maleate+Perindopril Arginine+FOSINOPRIL SODIUM+TRANDOLAPRIL+MOEXIPRIL HYDROCHLORIDE (ACEI Omission)	顧構糧簾鹽膚醖簾獵壓(繭遞鹹顧願築鑰遞淵鹹) = 糧積鬱構壓夢廠鏇窪襯製繭餘選壓製餘網襯鹹 (齋觸網齋襯鹽遞觸艱觸, 選鏇鏇鹽簾築鹹齋淵膚 ~ 繭淵壓衊簾製醖製遞蓋) 更多	-	2017-12-11
				ACEI continuation (ACEI Continuation)	顧構糧簾鹽膚醖簾獵壓(繭遞鹹顧願築鑰遞淵鹹) = 憲壓夢觸構窪範蓋構衊製繭餘選壓製餘網襯鹹 (齋觸網齋襯鹽遞觸艱觸, 餘製築餘夢製積鏇鬱獵 ~ 憲齋鏇艱鑰衊夢獵窪糧) 更多